GLP-1RA Use and Thyroid Cancer Risk
This secondary analysis of a target trial emulation of a comparative effectiveness study found that despite the low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk of new thyroid cancer diagnoses within the first year of GLP-1RA initiation compared to 3 other diabetes drugs. This finding may have been due to enhanced early detection; therefore, further research is necessary to understand the underlying causes of this association.
Authors
- Rozalina Grubina McCoy (ORCID: https://orcid.org/0000-0002-2289-3183)
- Jeph Herrin (ORCID: https://orcid.org/0000-0002-3671-3622)
- Mindy M. Mickelson (ORCID: https://orcid.org/0009-0004-3664-127X)
- David Toro-Tobón (ORCID: https://orcid.org/0000-0003-1910-4144)
- Yihong Deng
- Rodolfo Javier Galindo (ORCID: https://orcid.org/0000-0002-9295-3225)
- Eric C. Polley (ORCID: https://orcid.org/0000-0002-5152-8740)
- Juan Pablo Brito (ORCID: https://orcid.org/0000-0003-1840-1745)
- Guillermo E. Umpierrez (ORCID: https://orcid.org/0000-0002-3252-5026)
- Kavya Swarna
- Naykky Singh Ospina (ORCID: https://orcid.org/0000-0003-4240-6239)
- Hui Shao (ORCID: https://orcid.org/0000-0002-4088-546X)
- Víctor M. Montori (ORCID: https://orcid.org/0000-0003-0595-2898)
Institutions
- University of Maryland, Baltimore (US)
- Mayo Clinic (US)
- University of Miami (US)
- Emory University (US)
- Chicago Department of Public Health (US)
- Foundation for the National Institutes of Health (US)
- Yale University (US)
- University of Florida (US)
- University of Chicago (US)
- Woodruff Health Sciences Center (US)
- Optum (United States) (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- JAMA Otolaryngology–Head & Neck Surgery
- Published
- 2025-01-23
- DOI
- https://doi.org/10.1001/jamaoto.2024.4852
- Citations
- 34
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 46.04